Vimarsana
Biggest News Aggregation in the World

Alina Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alina Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alina Study Today - Breaking & Trending Today

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC - Vimarsana News

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC

Published: November 17, 2023

Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Source: onclive.com
Related Topics:
Patients With Early StageLung CancerNon Small Cell Lung CancerAlina TrialAlina StudyAdjuvant AlectinibDr Benjamin SolomonEarly Stage Alk Nsclc
Genentech: Alecensa Reduces Risk Of Disease Recurrence/ Death In ALK-Positive Early-Stage NSCLC - Vimarsana News

Genentech: Alecensa Reduces Risk Of Disease Recurrence/ Death In ALK-Positive Early-Stage NSCLC

Published: October 18, 2023

Genentech, Inc., affiliated to Swiss drug major Roche Holding AG (RHHBY), announced Wednesday results from the primary analysis of the Phase III ALINA study of Alecensa (alectinib) in people with anaplastic lymphoma kinase or ALK-positive non-small cell lung cancer or NSCLC.

Source: rttnews.com
Related Topics:
More Such Health NewsGenentech IncRoche HoldingDrug AdministrationEuropean Medicines AgencyEuropean Society Of Medical OncologyEuropean SocietyMedical OncologyEuropean MedicinesAnaplastic Lymphoma KinaseLecensa Alina Study